COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
02/05/2024
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales [...]
Ipsen appoints Keira Driansky as EVP, President of North America
02/05/2024
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13 [...]
Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord
02/05/2024
PARIS, FRANCE, 2 Mai 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondiale de spécialité, annonce aujourd'hui la nomination de Keira Driansky en tant que Vice-Présidente Exécutive, et Présidente [...]
IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US
02/05/2024
Louvain-La-Neuve, Belgium, 2 May 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy [...]
IBA signe un contrat avec Yale New Haven Health et Hartford HealthCare pour l’installation d’une solution de protonthérapie Proteus®ONE dans le Connecticut, aux États-Unis
02/05/2024
Louvain-la-Neuve, Belgique, le 2 mai 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules, annonce aujourd'hui avoir signé un contrat avec le Connecticut [...]
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
02/05/2024
EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and [...]
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
02/05/2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
02/05/2024
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and [...]
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS
02/05/2024
Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus ( [...]
Interim Report Q1 2024: GN Store Nord delivered organic revenue growth of 5% reaching an EBITA margin of 12.5%
02/05/2024
Highlights GN delivered continued execution across the three divisions resulting in 5% organic revenue growth for the Group The Hearing division delivered continued market share gains leading to 14% organic revenue [...]
CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant
02/05/2024
CARBIOS and Hündgen enter supply agreement for world’s first PET biorecycling plant From end 2026, Hündgen will supply 15kt/year of post-consumer PET flakes to CARBIOS’ first commercial plant Clermont-Ferrand, France, [...]
CARBIOS et Hündgen concluent un accord d’approvisionnement pour la première usine de biorecyclage du PET au monde
02/05/2024
CARBIOS et Hündgen concluent un accord d’approvisionnement pour la première usine de biorecyclage du PET au monde A partir de fin 2026, Hündgen fournira 15kt/an de paillettes de PET post-consommation à la première usine [...]
Three Pivotal Drug Policy Organizations Hold Media Briefing/Q&A on DEA Rescheduling of Cannabis
01/05/2024
Executives from MAPS, NORML, and MPP to Celebrate DEA Rescheduling of Cannabis to Schedule III Drug and Debunk Myths WASHINGTON, May 01, 2024 (GLOBE NEWSWIRE) -- What: The Multidisciplinary Association for Psychedelic [...]
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2024
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 [...]
Pennant Acquires Senior Living Community in Idaho
01/05/2024
EAGLE, Idaho, May 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2024
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]
Pennant Acquires Utah Home Health and Hospice Provider
01/05/2024
EAGLE, Idaho, May 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced [...]
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
01/05/2024
FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing [...]
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC
01/05/2024
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the [...]

Pages